Comparative Pharmacology
Head-to-head clinical analysis: AEROLATE III versus BRONKOSOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AEROLATE III versus BRONKOSOL.
AEROLATE III vs BRONKOSOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular cAMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.
Bronchodilator via beta-2 adrenergic receptor agonism, increasing intracellular cAMP, leading to smooth muscle relaxation in the airways.
Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.
2.5 mg (0.5 mL of 0.5% solution) via nebulization three to four times daily, as needed.
None Documented
None Documented
Terminal half-life 12-15 hours; clinically allows twice-daily dosing
Terminal elimination half-life is 3–4 hours; prolonged in hepatic impairment (up to 8 hours).
Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other
Primarily renal excretion as sulfate conjugates; unchanged drug accounts for <10% of excretion. Biliary/fecal excretion is minimal (<2%).
Category C
Category C
Bronchodilator
Bronchodilator